Effects of novel therapies new insights into old medicationsImproved understanding of the interactions between 2GPI, aPL Abs and cell-surface molecules such as annexins has led to the development of a potential therapy by blocking binding of anti-2GPI Abs to 2GPI. Ioannou et al. were able to demonstrate the use of a recombinant domain I peptide, which effectively inhibits binding of anti-2GPI Ab